Nothing Special   »   [go: up one dir, main page]

CO4980854A1 - PARTICULARLY AMIDED B-CELL INHIBITORS, THE PROCESS FOR THEIR PRODUCTION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM - Google Patents

PARTICULARLY AMIDED B-CELL INHIBITORS, THE PROCESS FOR THEIR PRODUCTION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

Info

Publication number
CO4980854A1
CO4980854A1 CO99007017A CO99007017A CO4980854A1 CO 4980854 A1 CO4980854 A1 CO 4980854A1 CO 99007017 A CO99007017 A CO 99007017A CO 99007017 A CO99007017 A CO 99007017A CO 4980854 A1 CO4980854 A1 CO 4980854A1
Authority
CO
Colombia
Prior art keywords
alkyl
carbon atoms
terminal position
amided
production
Prior art date
Application number
CO99007017A
Other languages
Spanish (es)
Inventor
Rainer Albert
Elsebeth Andersen
Alexander Hagenbach
Christoph Heusser
Papageorgiou Christos
Schreier Max H
Anette Wienand
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9802842.6A external-priority patent/GB9802842D0/en
Priority claimed from GBGB9810688.3A external-priority patent/GB9810688D0/en
Priority claimed from GBGB9826553.1A external-priority patent/GB9826553D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CO4980854A1 publication Critical patent/CO4980854A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se relaciona con un compuesto de lafórmula A: en donde cualquiera de: 1) Z es O; n es 0; T es un residuo: en donde: R6 es H; alquilo de 1 a 6 átomos de carbono opcionalmente sustituido en la posición terminal por halógeno, OH, NR7 R8 , COOH, CO-O-alquilo de 1 a 4 átomos de carbono, o CO-NR7 R8 ; alquilo de 1 a 6 átomos de carbono interrumpido por uno o más heteroátomos seleccionados a partir de N, o ó S, y sustituido en la posición terminal por halógeno, OH, NR7 R8 , COOH, CO-O-alquilo de 1 a 4 átomos de carbono, o CO-NR7 R8 ; OR9 ; NHR10 ; ciano; o formilo; Cada uno de R7 y R8 es independientemente H, alquilo de 1 a 4 átomos de carbono, ?-HO-alquilo de 1 a 4 átomos de carbono, CHO ó heterocicloalquilo de 1 a 4 átomos de carbono, o R7 y R8 forman junto con el átomo de nitrógeno con el que están enlazados, un anillo heterocíclico; R9 es alquilo de 1 a 6 átomos de carbono sustituido en la posición terminal por OH ó NR7 R8 ; R10 es un alquilo de 1 a 6 átomos de carbono sustituido en la posición terminal por OH ó NR7 R8 ; y W es un residuo: en donde: i) X es -CR1 =, en donde R1 es H, F, CF3 , alquilo de 1 a 4 átomos de carbono, ó NH2 ; ...The present invention relates to a compound of formula A: wherein any of: 1) Z is O; n is 0; T is a residue: where: R6 is H; alkyl of 1 to 6 carbon atoms optionally substituted at the terminal position by halogen, OH, NR7 R8, COOH, CO-O-alkyl of 1 to 4 carbon atoms, or CO-NR7 R8; alkyl of 1 to 6 carbon atoms interrupted by one or more heteroatoms selected from N, or or S, and substituted in the terminal position by halogen, OH, NR7 R8, COOH, CO-O-alkyl of 1 to 4 atoms carbon, or CO-NR7 R8; OR9; NHR10; cyano; or formyl; Each of R7 and R8 is independently H, alkyl of 1 to 4 carbon atoms,? -HO-alkyl of 1 to 4 carbon atoms, CHO or heterocycloalkyl of 1 to 4 carbon atoms, or R7 and R8 form together with the nitrogen atom to which they are attached, a heterocyclic ring; R9 is alkyl of 1 to 6 carbon atoms substituted in the terminal position by OH or NR7 R8; R10 is an alkyl of 1 to 6 carbon atoms substituted in the terminal position by OH or NR7 R8; and W is a residue: where: i) X is -CR1 =, where R1 is H, F, CF3, C 1-4 -alkyl, or NH2; ...

CO99007017A 1998-02-10 1999-02-08 PARTICULARLY AMIDED B-CELL INHIBITORS, THE PROCESS FOR THEIR PRODUCTION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM CO4980854A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9802842.6A GB9802842D0 (en) 1998-02-10 1998-02-10 Organic compounds
GBGB9810688.3A GB9810688D0 (en) 1998-05-19 1998-05-19 Organic compounds
GBGB9826553.1A GB9826553D0 (en) 1998-12-02 1998-12-02 Organic compounds

Publications (1)

Publication Number Publication Date
CO4980854A1 true CO4980854A1 (en) 2000-11-27

Family

ID=27269204

Family Applications (1)

Application Number Title Priority Date Filing Date
CO99007017A CO4980854A1 (en) 1998-02-10 1999-02-08 PARTICULARLY AMIDED B-CELL INHIBITORS, THE PROCESS FOR THEIR PRODUCTION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

Country Status (5)

Country Link
AR (1) AR015514A1 (en)
AU (1) AU2832399A (en)
CO (1) CO4980854A1 (en)
PE (1) PE20000281A1 (en)
WO (1) WO1999041239A1 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001277731A1 (en) * 2000-08-09 2002-02-18 Welfide Corporation Fused bicyclic amide compounds and medicinal use thereof
IL156315A0 (en) * 2000-12-07 2004-01-04 Cv Therapeutics Inc Abca-1 elevating compounds
EP1377549A1 (en) * 2001-03-12 2004-01-07 Millennium Pharmaceuticals, Inc. Functionalized heterocycles as modulators of chemokine receptor function and methods of use therefor
EP1417204B1 (en) 2001-08-15 2006-01-18 E. I. du Pont de Nemours and Company Ortho-heterocyclic substituted aryl amides for controlling invertebrate pests
WO2003059258A2 (en) 2001-12-21 2003-07-24 Cytokinetics, Inc. Compositions and methods for treating heart failure
EP2583678A3 (en) 2004-06-24 2013-11-13 Novartis Vaccines and Diagnostics, Inc. Small molecule immunopotentiators and assays for their detection
US8686048B2 (en) 2010-05-06 2014-04-01 Rhizen Pharmaceuticals Sa Immunomodulator and anti-inflammatory compounds
CA2804225C (en) * 2010-07-02 2018-05-01 Aska Pharmaceutical Co., Ltd. Heterocyclic compound and p27kip1 degradation inhibitor
EP2672963A4 (en) 2011-02-08 2015-06-24 Childrens Medical Center Methods for treatment of melanoma
EP2847165A2 (en) * 2012-04-02 2015-03-18 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Indole, indoline derivatives, compositions comprising them and uses thereof
TR201810944T4 (en) 2013-10-25 2018-08-27 Novartis Ag Ring-fused bicyclic pyridyl derivatives as Fgfr4 inhibitors.
US20180185341A1 (en) 2014-10-03 2018-07-05 Novartis Ag Use of ring-fused bicyclic pyridyl derivatives as fgfr4 inhibitors
US9802917B2 (en) 2015-03-25 2017-10-31 Novartis Ag Particles of N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide
US10730839B2 (en) * 2016-11-27 2020-08-04 Russell Dahl Quinolines as cytoprotective agents
WO2019057053A1 (en) * 2017-09-20 2019-03-28 北京加科思益新药研发有限公司 Fused ring derivative used as fgfr4 inhibitor

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1305458A (en) * 1969-02-26 1973-01-31
US3699123A (en) * 1970-03-24 1972-10-17 Sandoz Ltd 4-(3-amino-2-hydroxy-propoxy) indole derivatives
FR2121394A1 (en) * 1971-01-08 1972-08-25 Anvar 2-methyl indole 3-carboxylic acid amides - antiinflammatories analgesics, tranquillisers, fungicides, herbicides and inters
US5484944A (en) * 1993-10-27 1996-01-16 Neurogen Corporation Certain fused pyrrolecarboxanilides and their use as GABA brain receptor ligands

Also Published As

Publication number Publication date
AR015514A1 (en) 2001-05-02
AU2832399A (en) 1999-08-30
PE20000281A1 (en) 2000-05-15
WO1999041239A1 (en) 1999-08-19

Similar Documents

Publication Publication Date Title
CO4980854A1 (en) PARTICULARLY AMIDED B-CELL INHIBITORS, THE PROCESS FOR THEIR PRODUCTION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
ATE388958T1 (en) 4'-C-SUBSTITUTED 2-HALOADENOSINE DERIVATIVES
CO5040071A1 (en) DERIVATIVES OF BICYCLE AMINES, PROCESSES FOR THEIR PREPARATION, AND INSECTICIATED COMPOSITIONS THAT UNDERSTAND THEM
TW200604175A (en) Ortho substituted aryl or heteroaryl amide compounds
AR018892A1 (en) CARBON-SUBSTITUTED AMINOTIAZOL COMPOUNDS, USEFUL AS INHIBITORS OF CYCLINE DEPENDENT KINASES AND PHARMACEUTICAL COMPOSITIONS THAT CONCERN, METHOD FOR THE TREATMENT OF PROLIFERATIVE DISEASES, INFLAMMATION AND ARTHRITIS
GB9806692D0 (en) Benzoheterocyclic distamycin derivatives, process for preparing them and their use as antitumour agents
HUP0004227A2 (en) Direct ortho-metalation process for the synthesis of 5-(2-substituted-phenyl)-tetrazol derivatives
CO4990932A1 (en) DERIVATIVES OF 2,1,3-BENZOTIADIAZOLE AND PROCESS FOR ITS PREPARATION
HUP0004020A2 (en) Tricyclic triazolobenzazepine derivatives, process for producing the same, and their use as antiallergic agent
NZ332923A (en) Distamycin derivatives, process for preparing them, and their use as antitumor and antiviral agents
DK178388D0 (en) TRICYCLIC AMINES DERIVATED BY 2,3,5,6,7,8-HEXAHYDRONAPHTHO- (2,3-B) FURAN AND 2,3,6,7,8,9-HEXAHYDRO-5H-BENZOCYCLOHEPTA- (2,3) -B) FURAN, PROCEDURES FOR THEIR MANUFACTURING AND PHARMACEUTICAL AGENTS CONTAINING THEM
MY125037A (en) 1,2,3,4 tetrahydroquinoline derivatives
MEP12108A (en) Novel branched substituted amino derivatives of 3-amino-1-phenyl-1h[1,2,4]triazol, methods for producing them and pharmaceutical compositions containing them
ES2160158T3 (en) DERIVATIVES OF 4-INDOL-1-IL BUTIRIC ACID, ITS PREPARATION AND ITS USE AS INHIBITORS OF ALFA1-ADRENERGIC RECEPTORS AND TESTOSTERONE 5ALFA-REDUCTASAS.
MXPA04003568A (en) Aralkyl-tetrahydro-pyridines, their preparation and pharmaceutical compositions containing same.
DK0812838T3 (en) Pyridonecarboxylic acid derivatives substituted with bicyclic amino group, esters and salts thereof, and bicyclic amine as intermediate
GB9812211D0 (en) Cinnamoyl distamycin analogous derivatives,process for their preparation,and their use as antitumor agents
DE60000978D1 (en) 22R-HYDROXYCHOLESTA-8,14-DIENE DERIVATIVES FOR INHIBITING MEIOSE
ATE486886T1 (en) NEW BETULINIC ACID DERIVATIVES CONDENSED IN THE A-RING WITH A HETEROCYCLIC GROUP
NO955071D0 (en) monkey Ergoline derivatives as 5HT1A ligands
PE20001035A1 (en) DERIVATIVES OF BENZOXAZINE AND BENZOTHIAZINE AS INHIBITORS OF NITROGEN MONOXIDE SYNTHASE
HUP0003321A2 (en) Process for the preparation of 2-alkylthiobenzonitrile derivatives
UA83638C2 (en) 4-oxo-4,6,7,8-tetrahydro-pyrrolo[1,2-a]pyrazine-6-carboxamide compounds, process for the preparation thereof and pharmaceutical composition containing thereof
EA200900922A1 (en) NEW TRIAZABENZO [α] NAFTO [2,1,8-cde] AZULENA COMPOUNDS, METHOD OF THEIR PRODUCTION AND CONTAINING THEIR PHARMACEUTICAL COMPOSITIONS
EA200500654A1 (en) NEW SUBSTITUTED COMPOUNDS BENZO [E] [1,4] OXAZINO [3,2-G] IZOINDOL, METHOD FOR THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITIONS THERE ARE CONTAINED